Short Interest in Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) Decreases By 37.4%

Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) was the target of a large drop in short interest during the month of December. As of December 31st, there was short interest totaling 6,009 shares, a drop of 37.4% from the December 15th total of 9,599 shares. Based on an average daily trading volume, of 2,678 shares, the days-to-cover ratio is presently 2.2 days. Approximately 0.6% of the shares of the company are sold short. Approximately 0.6% of the shares of the company are sold short. Based on an average daily trading volume, of 2,678 shares, the days-to-cover ratio is presently 2.2 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Addex Therapeutics in a research report on Friday, January 9th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

Addex Therapeutics Trading Up 0.5%

Shares of Addex Therapeutics stock opened at $8.26 on Friday. Addex Therapeutics has a 1 year low of $6.51 and a 1 year high of $12.05. The company’s fifty day simple moving average is $8.07 and its 200-day simple moving average is $8.54. The company has a market cap of $10.15 million, a price-to-earnings ratio of -1.44 and a beta of 1.49.

Addex Therapeutics (NASDAQ:ADXN) last issued its quarterly earnings results on Thursday, December 4th. The company reported ($1.51) earnings per share for the quarter. The business had revenue of $0.04 million for the quarter.

Addex Therapeutics Company Profile

Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry.

The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease.